MSM: What the Evidence Covers, and What It Does Not

Abstract

Methylsulfonylmethane has a real human evidence base. It is about knees.

The randomised trials measure osteoarthritis pain, physical function and stiffness. The safety literature is reassuring at doses up to four grams a day. Neither says anything about cognition, and MSM is an ingredient in one of our cognitive formulations.

This article is about that gap, which we think is more instructive than either the evidence or its absence taken alone.

1.What MSM Is

Methylsulfonylmethane, also called dimethyl sulfone, is an organosulfur compound. Matthew Butawan, Rodney Benjamin and Richard Bloomer at the University of Memphis set out its profile in a 2017 review in Nutrients, and describe its most common use plainly: as an anti-inflammatory agent.

They list the outcomes on which supplementation has improved measures — inflammation, joint and muscle pain, oxidative stress, and antioxidant capacity. That is a coherent set, and it does not include a single cognitive endpoint.

On safety they are specific. MSM holds Generally Recognized As Safe status in the United States and is well tolerated by most people at doses up to four grams daily, with few and mild known side effects.

They are equally specific about what remains unsettled: initial evidence exists regarding the dose needed to provide benefit, with further work underway to establish the precise dose and time course.

2.The Trials

Eytan Debbi and colleagues in Israel randomised patients with knee osteoarthritis to MSM or placebo, in a study published in BMC Complementary and Alternative Medicine in 2011. Sixty patients were assessed by orthopaedic specialists and fifty met the criteria and were enrolled.

Outcomes were measured with WOMAC, the standard osteoarthritis instrument covering pain, stiffness and physical function. The report describes significant differences between treatment groups over time in physical function and total score, with improvements in pain and stiffness.

A 2023 randomised, double-blind, placebo-controlled trial by Ayaka Toguchi and colleagues, published in Nutrients, extended the question to a milder population: participants with mild knee pain rather than diagnosed osteoarthritis, with knee-related quality of life as the outcome.

Fifty participants is a small trial and neither of these is definitive. What they establish is that the endpoint being studied has been consistent for two decades, and it is the knee.

3.The Gap, Stated Plainly

MSM appears in Cognitive Essence. There is no human trial of MSM and cognition, no meta-analysis, and no authorised health claim of any kind for it in the European Union.

Our own formulation page has recorded this since before this article existed. The entry for MSM states that human trials concern osteoarthritis, an entirely different endpoint, and that no authorised claim exists. The page also notes that four ingredients in that concept — sodium, mastiha, saffron and MSM — carry no authorised health claim at all.

We are repeating it here because a formulation page is read by people who already went looking, and an article is read by people who did not.

The available inference for MSM in a cognitive product runs through inflammation: MSM reduces markers of inflammation, inflammation is implicated in cognitive ageing, therefore MSM might help cognition. Each step is defensible and the chain is not. That form of argument would license almost any anti-inflammatory compound for almost any outcome, and this library exists partly to refuse it.

4.What Would Change This

A randomised trial of MSM alone, at a stated dose, in humans, with a cognitive outcome specified in advance. It has not been done, and until it is, the honest description of MSM in a cognitive context is that it is there on mechanism rather than on evidence.

That is a weaker justification than we would want, and stating it is preferable to constructing a case from the joint literature.

It is worth adding what the joint literature does not suffer from: the trials are small but the compound is well characterised, the dosing is established, the safety margin is wide, and the outcome instrument is standard. This is not a shaky evidence base. It is a solid one pointing somewhere else.

Editorial Comment

Cognitive Essence contains MSM. We make no claim about what it does there, because there is no authorised claim to make and no human cognitive evidence to point at.

We could have written this article about knee pain, cited the trials approvingly, and left the reader to make the connection to a cognitive product themselves. That is how this is normally done, and it is why we are not doing it.

If joint pain rather than cognition is the actual concern, the doses in these trials are grams per day and the compound is inexpensive as a single ingredient. Buying a cognitive formulation for its MSM content would be an expensive way to obtain a small amount of it.

Persistent joint pain is also worth a diagnosis rather than a supplement. Osteoarthritis, inflammatory arthritis and several other causes are distinguishable and managed differently, and the trials above were conducted in people whose diagnosis was already established by a specialist.